<PAGE>
FORM 10-Q/A
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
(Mark One)
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934 for the quarterly period ended June 30, 1999, or
[_] Transition report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from ________________ to
_________________
COMMISSION FILE NUMBER 0-12943
CYPRESS BIOSCIENCE, INC.
(Exact Name of Registrant as specified in its charter)
DELAWARE 22-2389839
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO, CALIFORNIA 92121
(Address of principal executive offices) (zip code)
(858) 452-2323
(Registrant's telephone number including area code)
__________________________________
Indicate by check (X) whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [_]
AT AUGUST 6, 1999, 46,089,629 SHARES OF COMMON STOCK OF THE REGISTRANT WERE
OUTSTANDING.
<PAGE>
The Company hereby amends and restates the following page reference numbers
located in the table of contents as follows:
TABLE OF CONTENTS
Page
----
PART I - FINANCIAL INFORMATION
Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations................................ 9
Item 3 - Quantitative and Qualitative Disclosure About Market Risk.......... 14
<PAGE>
Item 2 Management's Discussion and Analysis of Financial Condition and
Results of Operations
The Company hereby amends and restates the second sentence of paragraph 5
of its "Results of Operations" subsection of its Management's Discussion and
Analysis of Financial Condition and Results of Operations, as follows:
"The increases in sales and marketing expenses of approximately 175% and
219% for the quarter and six months ended June 30, 1999, respectively, primarily
resulted from the hiring of a sales force and other activities associated with
the launch of the Prosorba column for RA in April 1999."
1.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Cypress Bioscience, Inc.
August 24, 1999 /s/ Jay D. Kranzler
- --------------------------- --------------------------------------------
Date
Jay D. Kranzler, M.D., Ph.D.
Chief Executive Officer and Chairman of the
Board
(Principal Executive Officer and Acting
Principal Accounting and Financial Officer)
16
